Skip NavigationSkip to Content
Return Return to Search Results

Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration

  1. Author:
    Choudhry, V.
    Zhang, M. Y.
    Harris, I.
    Sidorov, I. A.
    Vu, B.
    Dimitrov, A. S.
    Fouts, T.
    Dimitrov, D. S.

  2. Author Address

    NCI, Prot Interact Grp, CCRNP, CCR,NIH, Frederick, MD 21702 USA. SAIC Frederick Inc, NCI Frederick, BRP, Frederick, MD 21702 USA. Profectus BioSci Inc, Baltimore, MD 21227 USA.;Choudhry, V, NCI, Prot Interact Grp, CCRNP, CCR,NIH, Bldg 320,Room 8,POB B,Miller Dr, Frederick, MD 21702 USA.;vchoudhry@ncifcrf.gov dimitrov@nciferf.gov
    1. Year: 2006
    2. Date: Sep
  2. Journal: Biochemical and Biophysical Research Communications
    1. 348
    2. 3
    3. Pages: 1107-1115
  4. Type of Article: Article
  5. ISSN: 0006-291X
  1. Abstract:

    It has been observed that some antibodies, including the CD4-induced (CD4i) antibody IgG X5 and the gp41-specific antibody IgG 2F5. exhibit higher neutralizing activity in PBMC-based assays than in cell line based assays [J.M. Binley, T. Wrin, B. Korber, M.B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, C.J. Petropoulos, D.R. Burton, Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type I monoclonal antibodies, J. Virol. 78 (2004) 13232-13252]. It has been hypothesized that the lower CCR5 concentration on the surface of the CD4 T lymphocytes compared to that on cell lines used for the neutralization assays could be a contributing factor to the observed differences in neutralizing activity. To test this hypothesis and to further elucidate the contribution of CCR5 concentration differences on antibody neutralizing activity, we used a panel of HeLa cell lines with well-defined and differential surface concentrations of CCR5 and CD4 in a pseudovirus-based assay. We observed that the CCR5 cell surface concentration but not the CD4 concentration had a significant effect on the inhibitory activity of X5 and several other CD4i antibodies including 1713 and m9, as well as that of the gp41-specifc antibodies 2F5 and 4E10 but not on that of the CD4 binding site antibody (CD4bs), b12. The 50% inhibitory concentration (IC50) decreased up to two orders of magnitude in cell lines with low CCR5 concentration corresponding to that in CD4 T cells used in PBMC-based assays (about 10(3) per cell) compared to cell lines with high CCR5 concentration (about 10(4) or more). Our results suggest that the CCR5 cell surface concentration could be a contributing factor to the high neutralizing activities of some antibodies in PBMC-based-assays but other factors could also play an important role. These findings could have implications for development of vaccine immunogens based on the epitopes of X5 and other CD4i antibodies, for elucidation of the mechanisms of HIV-1 neutralization by antibodies, and for design of novel therapeutic approaches. Published by Elsevier Inc.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.bbrc.2006.07.163
  3. View record in Web of Science®
  4. WOS: 000240166500045

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel